Comparison · NCT03503773-9848463f
Treatment Arm: vs Sham Control Arm: Number of Participants With Major Adverse Events (MAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment Arm: vs Sham Control Arm: Number of Participants With Major Adverse Events (MAEs). Trial comparisons, record NCT03503773-9848463f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03503773-9848463f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.02 | 0.00354 | 0.105 | wilson | |
| Risk in group 2 | 0.0179 | 0.00316 | 0.0945 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00214 | -0.0762 | 0.0884 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.12 | 0.0719 | 17.4 | log | |
| Odds ratio, group 1 over group 2 | 1.12 | 0.0684 | 18.4 | log | |
| Number needed to treat, for one more participant with the outcome on Treatment Arm: than on Sham Control Arm | 467 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment Arm: | Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter~Alcohol: Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries | 1 | 50 | OG001 |
| Group 2 | Sham Control Arm | Only renal angiography performed~Sham control: endovascular, renal angiography | 1 | 56 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Major Adverse Events (MAEs)
- Description
- Number of participants with major adverse events (MAEs) 30 days post-procedure
- Time frame
- 30 days post procedure
- Population
Source ClinicalTrials.gov
Trial
- Title
- The TARGET BP OFF-MED Trial
- NCT number
- NCT03503773
- Phases
- PHASE2
- Conditions
- Hypertension, Hypertension,Essential
- Interventions
- Alcohol, Sham control
- Lead sponsor
- Ablative Solutions, Inc.
- Results first posted
- 2024-10-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03503773?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03503773-9848463f